Table 2.
Distribution of HIV-1 subtypes and K65R across subtypesa
| Subtype | No. (%) of patients | K65R prevalence (%; 95% CI) | Observation time (yrs) | K65R selection rate (95% CI) |
|---|---|---|---|---|
| A | 84 (2.7) | 5 (6.0; 2.7–13.0) | 105.1 | 4.8 (1.5–11.1) |
| B | 2,386 (77.4) | 209 (8.8; 7.7–10.0) | 2,924.2 | 7.1 (6.2–8.1) |
| C | 105 (3.4) | 17 (16.2; 10.4–24.4) | 106.4 | 15.9 (9.3–25.5) |
| F | 55 (1.8) | 3 (5.5; 1.9–14.9) | 67.7 | 4.4 (0.9–12.9) |
| G | 333 (10.8) | 40 (12.0; 8.9–15.9) | 490.6 | 8.2 (5.8–11.1) |
| CRF 02_AG | 116 (3.8) | 11 (9.5; 5.4–16.2) | 127.4 | 8.6 (4.3–15.4) |
a
For each subtype, the table shows the number of study patients as an absolute number and as a percentage, the number of K65R cases as an absolute number and as a percentage with 95% confidence intervals (CI), the total observation time in patient-years of tenofovir experience in the current therapy, and K65R selection rate as the number of K65R events per 100 patient-years with 95% confidence intervals.